FDA Approves Oral Treatment for Advanced Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved giredestrant in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer based on results from the phase 3 evERA clinical trial, led by investigators at Dana-Farber Cancer Institute.

The approval marks an important advance for patients with estrogen receptor-positive (ER+), HER2-negative advanced breast cancer, the most common form of metastatic breast cancer. In the evERA study, the combination of giredestrant and everolimus significantly improved progression-free survival (PFS) compared with a standard-of-care combination of endocrine therapy and everolimus.

"As oncologists we are always looking for better and more effective treatments for patients with metastatic breast cancer, particularly when their disease progresses on endocrine therapies and CDK4/6 inhibitors," said Erica Mayer, MD, MPH, Director of Breast Cancer Clinical Research at Dana-Farber and principal investigator of the evERA study. "Today's FDA approval of giredestrant gives patients an important new therapeutic option which substantially improves disease control while also providing the convenience of an all-oral regimen."

Approximately 70% of breast cancers are estrogen receptor-positive. Although treatments such as CDK4/6 inhibitors have significantly improved outcomes for patients with advanced disease, treatment options can become more limited when tumors develop resistance to endocrine therapies and progress following these treatments.

Giredestrant is a next-generation selective estrogen receptor degrader and full antagonist (SERD). It works by binding to the estrogen receptor and promoting its degradation, preventing estrogen from stimulating cancer cell growth. Everolimus is a targeted therapy that inhibits mTOR, a protein involved in cell growth and survival.

The FDA approval is based on findings from the global phase 3 evERA study, which evaluated giredestrant in combination with everolimus compared with standard-of-care endocrine therapy plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer. The study enrolled 373 patients, approximately 55% of whom had mutations in the estrogen receptor gene (ESR1).

After a median follow-up of 18.6 months, patients whose tumors harbored an ESR1 mutation and received giredestrant plus everolimus experienced a median progression-free survival of 10 months, compared with 5.5 months among patients receiving the standard-of-care combination. This represented a 63% reduction in the risk of disease progression or death.

In the overall study population, including patients with and without ESR1 mutations, median progression-free survival was 8.8 months for patients receiving giredestrant plus everolimus, compared with 5.5 months for those receiving standard-of-care treatment, representing a 44% reduction in the risk of disease progression or death.

Initial findings from the evERA study were presented at the 2025 Congress of the European Society for Medical Oncology. The study results were subsequently published in the New England Journal of Medicine on October 1, 2026.

The evERA Breast Cancer study was funded by F. Hoffmann-La Roche Ltd.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.